Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study
Open Access
- 19 February 2020
- journal article
- research article
- Published by S. Karger AG in Liver Cancer
- Vol. 9 (3), 308-325
- https://doi.org/10.1159/000505692
Abstract
Introduction: The benefits of combining transarterial chemoembolization (TACE) and sorafenib (TACE-S) over TACE alone for treatment of unresectable hepatocellular carcinoma (HCC) remain controversial. Yet, such populations are heterogeneous in terms of baseline characteristics. Objective: To investigate the predictors of survival benefits from added sorafenib and identify the potential candidates for TACE-S. Methods: This multicenter observational study was conducted in 17 Chinese tertiary hospitals for patients with unresectable, liver-confined HCC. Eligible patients with performance status score of ≤1 and Child-Pugh score of ≤7 were treated with TACE or TACE-S. Interactions between treatment and baseline variables were evaluated to find indicators for survival benefits, based on which the patients were stratified. Multivariate models adjusted for baseline characteristics or propensity score were used to compare overall survival (OS) and time to tumor progression (TTP). Results: From January 2009 to December 2015, 1,719 consecutive patients received TACE (n = 1,406) or TACE-S (n = 313). Although TACE-S compared with TACE improved TTP (adjusted hazard ratio [HR] 0.75, p = 0.008), no difference in OS was observed (adjusted HR 0.87, p = 0.090). Nevertheless, the tumor burden (sum of maximum diameter of largest tumor [cm] and tumor number) and albumin-bilirubin (ALBI) score independently predicted the survival benefits from added sorafenib (interaction p< 0.001). For patients with either moderate tumor burden (7–13) or low ALBI score (no more than –2.8) defined as candidates, TACE-S prolonged OS (adjusted HR 0.73, p = 0.003) and TTP (adjusted HR 0.72, p = 0.014) compared to TACE alone, whereas its superiority disappeared in non-candidates. Conclusions: Not all unresectable HCC patients but those with moderate tumor burden or low ALBI score achieve survival benefits from TACE-S compared with TACE alone. Future randomized controlled trials focusing on the subset are warranted.Keywords
This publication has 39 references indexed in Scilit:
- Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?Liver Cancer, 2013
- Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment DecisionsSeminars in Liver Disease, 2012
- Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinomaJournal of Hepatology, 2012
- TACE with or without systemic therapy?Journal of Hepatology, 2012
- Perspectives on The Design of Clinical Trials Combining Transarterial Chemoembolization and Molecular Targeted TherapyLiver Cancer, 2012
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in ItalyJournal of Hepatology, 2011
- TACE and Sorafenib: A Good Marriage?Journal of Clinical Oncology, 2011
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinomaEuropean Journal of Cancer, 2011
- The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinomaAlimentary Pharmacology & Therapeutics, 2011
- Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301Journal of Clinical Oncology, 2009